Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $24,892.14 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 546 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $45.59, for a total value of $24,892.14. Following the completion of the sale, the chief executive officer now owns 672,518 shares of the company’s stock, valued at $30,660,095.62. This trade represents a 0.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Twist Bioscience Stock Down 6.0 %

NASDAQ:TWST traded down $2.89 during trading hours on Tuesday, reaching $45.62. 814,483 shares of the stock were exchanged, compared to its average volume of 657,996. The business has a 50-day moving average of $46.16 and a two-hundred day moving average of $46.51. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a market capitalization of $2.71 billion, a price-to-earnings ratio of -12.67 and a beta of 1.85.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TWST. Barclays dropped their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Leerink Partners upped their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Scotiabank increased their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th. Finally, Robert W. Baird increased their price objective on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.90.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the third quarter worth $34,000. Signaturefd LLC lifted its stake in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience in the second quarter valued at $61,000. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the third quarter valued at $95,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.